Carna Biosciences,Inc. [4572.T]
TOKYO, Jul 01 (Pulse News Wire) – Carna Biosciences,inc. (4572.T) reported the exercise status of its docirbrutinib development rights for June 2026.
A total of 400 options (representing 0.51% of the total issuance) were exercised during the month, resulting in the delivery of 40,000 shares. As of the end of May, there were 76,503 outstanding options, which decreased to 76,103 by the end of June.
The exercise ratio was calculated based on the total number of issued options, standing at 7,650,300%. All exercises occurred without exceeding the exercise limits set according to the Tokyo Stock Exchange's listing regulations and the Securities Association’s rules for third-party allotment increases.
On June 15 and June 26, 200 options were exercised, reducing the remaining unexercised options to 296.1 and 200, respectively.
🟢 Confidence: High AI-translated content.